Tekmira Pharmaceuticals Corp. said on Wednesday that it is changing its board of directors members as part of its business combination with OnCore Biopharma, Inc.
The newly combined company’s board will include Chairman of the Board Vivek Ramaswamy, Richard Henriques Jr., Mark Murray, Keith Manchester, William Symonds, Frank Karbe and Herbert Conrad.
Conrad will be an important asset to the board. He has served as chairman at Pharmasset, Inc. He also was U.S. president and a member of the executive committee and board of directors of Roche Pharmaceutical Division.
These changes were set forth by the company’s proxy circular when the companies agreed to merge.
Tekmira is a leading company that develops RNA interference therapeutics.
OnCore Biopharma, Inc., specializes in developing and marketing specifically oral cures. OnCore’s main treatments are for hepatitis B infection. OnCore has a team uniquely dedicated to creating these drug candidates.